GlassScriptPhysician profile
Jenna A Brinker
NPI 1619553070
$2,341.94
in general payments reported to CMS, 2019-2025
27 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $758 · 2023: $668 · 2024: $407 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,283.86 | 2022-2025 | |
| Horizon Therapeutics Plc | $86.86 | 2021-2022 | |
| Amgen INC. | $78.60 | 2021-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $76.44 | 2021 | |
| Emd Serono, INC. | $74.25 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $73.68 | 2022 | |
| Sk Life Science, INC. | $71.03 | 2021-2022 | |
| Avion Pharmaceuticals | $63.37 | 2022 | |
| Ucb, INC. | $61.61 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $54.37 | 2021-2023 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $46.49 | 2022 | |
| Jazz Pharmaceuticals INC. | $46.01 | 2021-2022 | |
| Pfizer INC. | $36.98 | 2024 | |
| Genzyme Corporation | $33.75 | 2022 | |
| Ge Healthcare | $33.03 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.52 | 2023 | |
| Lilly USA, LLC | $29.94 | 2023 | Reyvow, Emgality, Amyvid |
| Impel Pharmaceuticals INC. | $24.62 | 2023 | Trudhesa |
| Biogen, INC. | $19.88 | 2022 | |
| Corium, LLC | $18.35 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.35 | 2022 | |
| Sumitomo Pharma America, INC. | $15.64 | 2023 | Aptiom |
| Kyowa Kirin, INC. | $14.60 | 2021 | |
| Neurelis, INC. | $14.33 | 2021 | |
| Neurocrine Biosciences, INC. | $13.03 | 2021 | |
| Acorda Therapeutics, INC | $12.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Brinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.